Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295046 | 0.84 | CYP2C19 (0.64) | CYP2C19HIF1AMAPTKIF11KMT2A | |
| SCHEMBL2300536 | 0.84 | CYP2C19 (0.64) | CYP2C19HIF1AMAPTKIF11KMT2A | |
| SCHEMBL167044 | 0.84 | CYP2C19 (0.64) | CYP2C19HIF1AMAPTKIF11KMT2A | |
| SCHEMBL1920886 | 0.83 | MIF (0.61) | CYP2C19HIF1ANPC1MAPTRAB9A | |
| SCHEMBL1585458 | 0.83 | CYP2C19 (0.44) | CYP2C19HIF1ANPC1RAB9AKIF11 | |
| SCHEMBL17047210 | 0.83 | MIF (0.61) | CYP2C19HIF1ANPC1MAPTRAB9A | |
| SCHEMBL831691 | 0.83 | MIF (0.61) | CYP2C19HIF1ANPC1MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL5860902 | 0.82 | CYP2C19 (0.62) | CYP2C19HIF1AMAPTKIF11KMT2A | |
| SCHEMBL7236788 | 0.80 | ALDH1A1 (0.49) | NPC1MAPTRAB9AKIF11KMT2A | |
| SCHEMBL31294691 | 0.80 | CYP2C19 (0.48) | CYP2C19HIF1ANPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477976-A1 | QUINAZOLINONE DERIVATIVES AS VIRAL POLYMERASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-07-25 | — | — | EP | disclosed |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011032277-A1 | QUINAZOLINONE DERIVATIVES AS VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | CYP2C19 712/4885HIF1A 3049/4885NPC1 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.